{"name":"Guangzhou Yipinhong Pharmaceutical CO.,LTD","slug":"guangzhou-yipinhong-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Clindamycin palmitate hydrochloride dispersible tablet","genericName":"Clindamycin palmitate hydrochloride dispersible tablet","slug":"clindamycin-palmitate-hydrochloride-dispersible-tablet","indication":"Other","status":"marketed"},{"name":"Fuganlin Oral Liquid","genericName":"Fuganlin Oral Liquid","slug":"fuganlin-oral-liquid","indication":"Other","status":"marketed"},{"name":"PNA 40mg","genericName":"PNA 40mg","slug":"pna-40mg","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"PNA","genericName":"PNA","slug":"pna","indication":"Treatment of various bacterial infections","status":"marketed"},{"name":"Xiaoer Jiebiao Oral Liquid","genericName":"Xiaoer Jiebiao Oral Liquid","slug":"xiaoer-jiebiao-oral-liquid","indication":"Pediatric fever associated with common cold and upper respiratory infections","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Alprostadil Liposomes for Injection","genericName":"Alprostadil Liposomes for Injection","slug":"alprostadil-liposomes-for-injection","indication":"Pulmonary hypertension","status":"phase_2"}]}],"pipeline":[{"name":"Clindamycin palmitate hydrochloride dispersible tablet","genericName":"Clindamycin palmitate hydrochloride dispersible tablet","slug":"clindamycin-palmitate-hydrochloride-dispersible-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alprostadil Liposomes for Injection","genericName":"Alprostadil Liposomes for Injection","slug":"alprostadil-liposomes-for-injection","phase":"phase_2","mechanism":"vasodilation via prostaglandin E1 receptor agonism","indications":["Pulmonary hypertension","Cerebral vasospasm"],"catalyst":""},{"name":"Fuganlin Oral Liquid","genericName":"Fuganlin Oral Liquid","slug":"fuganlin-oral-liquid","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PNA","genericName":"PNA","slug":"pna","phase":"marketed","mechanism":"PNA is a type of antimicrobial peptide that works by disrupting bacterial cell membranes.","indications":["Treatment of various bacterial infections"],"catalyst":""},{"name":"PNA 40mg","genericName":"PNA 40mg","slug":"pna-40mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Xiaoer Jiebiao Oral Liquid","genericName":"Xiaoer Jiebiao Oral Liquid","slug":"xiaoer-jiebiao-oral-liquid","phase":"marketed","mechanism":"Xiaoer Jiebiao Oral Liquid is a traditional Chinese medicine formulation that promotes fever resolution and supports immune function in pediatric patients.","indications":["Pediatric fever associated with common cold and upper respiratory infections","Fever management in children"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOcEcxLW9fQU5DNjNLbFpFX2djbkZaTnQwMU1SS2tua0g3MFpkdmIzZnVOM3VKb2xTZlBXd3Vyd1I0NkMtUVNLYmN3aUxpQ1VJbS1sN2JfX0JiZllnMEUtakJydWNWNTdZSGVCcV9tUVdGV2hNSmFLelpuWTVNS01kakFoRTVld201S19qZ3FxTGo3bGZmekdObWg4X2FucUR5TjQ3d0wxc1BycWVlM3E2T050MDk?oc=5","date":"2019-01-02","type":"pipeline","source":"Bloomberg.com","summary":"Even After a $46 Billion Plunge, China's Drugmakers May Have a Long Way to Fall - Bloomberg.com","headline":"Even After a $46 Billion Plunge, China's Drugmakers May Have a Long Way to Fall","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"marketed":4,"phase_2":1,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}